Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Shares Outstanding (Diluted Average) (2020 - 2025)

Cytek Biosciences' Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $126.9 million for Q2 2025.

  • For Q2 2025, Shares Outstanding (Diluted Average) fell 3.24% year-over-year to $126.9 million; the TTM value through Jun 2025 reached $126.9 million, down 3.24%, while the annual FY2023 figure was $135.3 million, 2.37% down from the prior year.
  • Shares Outstanding (Diluted Average) reached $126.9 million in Q2 2025 per CTKB's latest filing, down from $131.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $138.6 million in Q4 2022 to a low of $36.2 million in Q2 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $121.1 million, with a median of $132.8 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Diluted Average): skyrocketed 69.93% in 2022, then fell 3.49% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $81.5 million in 2021, then skyrocketed by 69.93% to $138.6 million in 2022, then fell by 2.37% to $135.3 million in 2023, then decreased by 3.08% to $131.1 million in 2024, then fell by 3.19% to $126.9 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Shares Outstanding (Diluted Average) are $126.9 million (Q2 2025), $131.1 million (Q3 2024), and $131.2 million (Q2 2024).